Friday Satellite Symposia
Clinical Practice (Health Services and Quality), Therapies, Adverse Events
Room 6DE
(San Diego Convention Center)
Chair:
Krish Patel, MD, Swedish Cancer Institute
Disclosures:
Patel: Pharmacyclics/Janssen: Consultancy, Research Funding; Sunesis Pharmaceuticals: Research Funding; Nurix: Research Funding; TG Therapeutics: Consultancy, Speakers Bureau; AstraZeneca: Consultancy, Research Funding, Speakers Bureau; Caribou Biosciences: Consultancy; Fate Therapeutics: Research Funding; Kite: Consultancy, Research Funding, Speakers Bureau; Loxo Oncology: Consultancy, Research Funding; Genentech/Roche: Consultancy, Research Funding; MEI Pharma: Consultancy, Research Funding; Trillium Therapeutics/Pfizer: Consultancy, Research Funding; Xencor: Consultancy, Research Funding; Curis, Inc: Research Funding; Epizyme: Consultancy, Research Funding; ADC Therapeutics: Consultancy; CRISPR Therapeutics: Research Funding; BeiGene: Consultancy; Morphosys: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; Merck: Consultancy, Research Funding; Adaptive Biotechnologies: Research Funding; Abbvie: Consultancy.
Speakers:
Krish Patel, MD, Swedish Cancer Institute
,
Peter A. Riedell, MD, University of Chicago
and
Douglas Burgoyne, PharmD, FAMCP, University of Utah
Disclosures:
Patel: MEI Pharma: Consultancy, Research Funding; CRISPR Therapeutics: Research Funding; Genentech/Roche: Consultancy, Research Funding; Kite: Consultancy, Research Funding, Speakers Bureau; Trillium Therapeutics/Pfizer: Consultancy, Research Funding; Merck: Consultancy, Research Funding; Curis, Inc: Research Funding; Caribou Biosciences: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; TG Therapeutics: Consultancy, Speakers Bureau; Morphosys: Consultancy; Fate Therapeutics: Research Funding; Nurix: Research Funding; Xencor: Consultancy, Research Funding; BeiGene: Consultancy; Loxo Oncology: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding, Speakers Bureau; Epizyme: Consultancy, Research Funding; Pharmacyclics/Janssen: Consultancy, Research Funding; Sunesis Pharmaceuticals: Research Funding; ADC Therapeutics: Consultancy; Adaptive Biotechnologies: Research Funding; Abbvie: Consultancy. Riedell: Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; CVS Caremark: Consultancy; MorphoSys: Research Funding; Nurix Therapeutics: Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Intellia Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Nektar Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy; Tessa Therapeutics: Research Funding; Nkarta: Research Funding; Roche: Research Funding; Xencor: Research Funding; Genmab: Consultancy; ADC Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Consultancy; Bristol Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genmab: Membership on an entity's Board of Directors or advisory committees; Kite/Gilead: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Karyopharm Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Fate Therapeutics: Research Funding; Calibr: Research Funding; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sana Biotechnology: Consultancy; BeiGene: Membership on an entity's Board of Directors or advisory committees; Celgene/ Bristol-Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; CRISPR Therapeutics: Research Funding.
On Demand program will be available here December 28, 2023.
Join expert DLBCL faculty as they take a deep dive into the latest clinical evidence and practical considerations for evidence-based integration of antibody-based therapies into treatment plans for DLBCL. Informed by real-world data from a recent quality improvement initiative, this satellite symposium will support DLBCL care teams in examining the latest evidence, differentiating new and emerging antibody-based therapies for DLBCL, and addressing barriers to novel therapy adoption. The topics for discussion by the expert faculty panel will be supported by clinical cases and enhanced by interactive polling questions and live questions submitted by attendees throughout the presentation. Additionally, a whiteboard animation video will be featured during the presentation, designed to illustrate the unique mechanisms of action of new and emerging novel, targeted antibody-based therapies for DLBCL. Altogether, this satellite symposium will harness real-world experiences providing DLBCL care to deepen the impact of the education on new and emerging antibody-based therapy, utilizing a case-based approach to provide a basis for discussion and strategy to enhance patient-centered care.
denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.